Mean and standard error of ex vivo EBV-specific IFN-γ spot-forming cells following stimulation with peptide epitopes (SFC/10⁶ PBMC). Responses were assessed before therapy (Before Rx) and 6 months (6m) and 12 months (12m) following diagnosis. The “6m” and “12m” columns include only data from newly diagnosed patients who went on to attain remission. These responses were compared with HL patients in long-term remission and healthy seropositive individuals. Panels A-C show data irrespective of EBV-tumor status. In panels A-B and D, “n” refers to the number of assays performed, with the number of patients shown in parentheses. (A) A cross-sectional analysis of LMP1/2-specific ELISPOT responses in HL patients at different time points and in healthy virus carriers. (B) A comparison of T-cell responses directed toward LMP1/2, EBNA3/4/6, and lytic epitopes in ND/RL HL patients and healthy virus carriers. (C) A matched-pair analysis of LMP1/2, EBNA3/4/6, and lytic epitope-specific CD8⁺ T-cell responses in HL patients both before and after receiving chemotherapy (Before Rx and After Rx). (D) LMP1/2-specific CD8⁺ T-cell responses in ND/RL EBV-positive and EBV-negative HL patients and ELISPOT responses in ND/RL HL patients with respect to clinical stage and Hasenclever/Diehl International Prognostic Score. In panels A and B, asterisks denote statistical significance.